Cargando…

Molecular probe technology detects bacteria without culture

BACKGROUND: Our ultimate goal is to detect the entire human microbiome, in health and in disease, in a single reaction tube, and employing only commercially available reagents. To that end, we adapted molecular inversion probes to detect bacteria using solely a massively multiplex molecular technolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyman, Richard W, St Onge, Robert P, Kim, Hyunsung, Tamaresis, John S, Miranda, Molly, Aparicio, Ana Maria, Fukushima, Marilyn, Pourmand, Nader, Giudice, Linda C, Davis, Ronald W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316761/
https://www.ncbi.nlm.nih.gov/pubmed/22404909
http://dx.doi.org/10.1186/1471-2180-12-29
_version_ 1782228465193320448
author Hyman, Richard W
St Onge, Robert P
Kim, Hyunsung
Tamaresis, John S
Miranda, Molly
Aparicio, Ana Maria
Fukushima, Marilyn
Pourmand, Nader
Giudice, Linda C
Davis, Ronald W
author_facet Hyman, Richard W
St Onge, Robert P
Kim, Hyunsung
Tamaresis, John S
Miranda, Molly
Aparicio, Ana Maria
Fukushima, Marilyn
Pourmand, Nader
Giudice, Linda C
Davis, Ronald W
author_sort Hyman, Richard W
collection PubMed
description BACKGROUND: Our ultimate goal is to detect the entire human microbiome, in health and in disease, in a single reaction tube, and employing only commercially available reagents. To that end, we adapted molecular inversion probes to detect bacteria using solely a massively multiplex molecular technology. This molecular probe technology does not require growth of the bacteria in culture. Rather, the molecular probe technology requires only a sequence of forty sequential bases unique to the genome of the bacterium of interest. In this communication, we report the first results of employing our molecular probes to detect bacteria in clinical samples. RESULTS: While the assay on Affymetrix GenFlex Tag16K arrays allows the multiplexing of the detection of the bacteria in each clinical sample, one Affymetrix GenFlex Tag16K array must be used for each clinical sample. To multiplex the clinical samples, we introduce a second, independent assay for the molecular probes employing Sequencing by Oligonucleotide Ligation and Detection. By adding one unique oligonucleotide barcode for each clinical sample, we combine the samples after processing, but before sequencing, and sequence them together. CONCLUSIONS: Overall, we have employed 192 molecular probes representing 40 bacteria to detect the bacteria in twenty-one vaginal swabs as assessed by the Affymetrix GenFlex Tag16K assay and fourteen of those by the Sequencing by Oligonucleotide Ligation and Detection assay. The correlations among the assays were excellent.
format Online
Article
Text
id pubmed-3316761
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33167612012-04-01 Molecular probe technology detects bacteria without culture Hyman, Richard W St Onge, Robert P Kim, Hyunsung Tamaresis, John S Miranda, Molly Aparicio, Ana Maria Fukushima, Marilyn Pourmand, Nader Giudice, Linda C Davis, Ronald W BMC Microbiol Methodology Article BACKGROUND: Our ultimate goal is to detect the entire human microbiome, in health and in disease, in a single reaction tube, and employing only commercially available reagents. To that end, we adapted molecular inversion probes to detect bacteria using solely a massively multiplex molecular technology. This molecular probe technology does not require growth of the bacteria in culture. Rather, the molecular probe technology requires only a sequence of forty sequential bases unique to the genome of the bacterium of interest. In this communication, we report the first results of employing our molecular probes to detect bacteria in clinical samples. RESULTS: While the assay on Affymetrix GenFlex Tag16K arrays allows the multiplexing of the detection of the bacteria in each clinical sample, one Affymetrix GenFlex Tag16K array must be used for each clinical sample. To multiplex the clinical samples, we introduce a second, independent assay for the molecular probes employing Sequencing by Oligonucleotide Ligation and Detection. By adding one unique oligonucleotide barcode for each clinical sample, we combine the samples after processing, but before sequencing, and sequence them together. CONCLUSIONS: Overall, we have employed 192 molecular probes representing 40 bacteria to detect the bacteria in twenty-one vaginal swabs as assessed by the Affymetrix GenFlex Tag16K assay and fourteen of those by the Sequencing by Oligonucleotide Ligation and Detection assay. The correlations among the assays were excellent. BioMed Central 2012-03-09 /pmc/articles/PMC3316761/ /pubmed/22404909 http://dx.doi.org/10.1186/1471-2180-12-29 Text en Copyright ©2012 Hyman et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Methodology Article
Hyman, Richard W
St Onge, Robert P
Kim, Hyunsung
Tamaresis, John S
Miranda, Molly
Aparicio, Ana Maria
Fukushima, Marilyn
Pourmand, Nader
Giudice, Linda C
Davis, Ronald W
Molecular probe technology detects bacteria without culture
title Molecular probe technology detects bacteria without culture
title_full Molecular probe technology detects bacteria without culture
title_fullStr Molecular probe technology detects bacteria without culture
title_full_unstemmed Molecular probe technology detects bacteria without culture
title_short Molecular probe technology detects bacteria without culture
title_sort molecular probe technology detects bacteria without culture
topic Methodology Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316761/
https://www.ncbi.nlm.nih.gov/pubmed/22404909
http://dx.doi.org/10.1186/1471-2180-12-29
work_keys_str_mv AT hymanrichardw molecularprobetechnologydetectsbacteriawithoutculture
AT stongerobertp molecularprobetechnologydetectsbacteriawithoutculture
AT kimhyunsung molecularprobetechnologydetectsbacteriawithoutculture
AT tamaresisjohns molecularprobetechnologydetectsbacteriawithoutculture
AT mirandamolly molecularprobetechnologydetectsbacteriawithoutculture
AT aparicioanamaria molecularprobetechnologydetectsbacteriawithoutculture
AT fukushimamarilyn molecularprobetechnologydetectsbacteriawithoutculture
AT pourmandnader molecularprobetechnologydetectsbacteriawithoutculture
AT giudicelindac molecularprobetechnologydetectsbacteriawithoutculture
AT davisronaldw molecularprobetechnologydetectsbacteriawithoutculture